Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP7 | Q93009 | 17/20 | 0.65 |
| ▸ | USP19 | O94966 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GPR183 | P32249 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30063698 | 0.87 | USP7 (0.83) | USP7 | |
| SCHEMBL20864300 | 0.87 | USP7 (0.83) | USP7 | |
| SCHEMBL26036413 | 0.87 | USP7 (0.57) | USP7USP19 | |
| SCHEMBL26036207 | 0.86 | USP7 (0.80) | USP7 | |
| SCHEMBL26036212 | 0.86 | USP7 (0.80) | USP7 | |
| SCHEMBL26036285 | 0.83 | USP7 (0.52) | USP7GPR183 | |
| SCHEMBL26036429 | 0.82 | USP7 (0.55) | USP7USP19MEN1KMT2A | |
| SCHEMBL26036424 | 0.80 | USP7 (0.53) | USP7USP19 | |
| SCHEMBL14747840 | 0.80 | USP7 (0.61) | USP7 | |
| SCHEMBL14735116 | 0.79 | USP7 (1.00) | USP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265070-A1 | NOVEL USP7 INHIBITORS FOR TREATING MULTIPLE MYELOMA | DANA-FARBER CANCER INSTITUTE, INC. | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265070-A1 | NOVEL USP7 INHIBITORS FOR TREATING MULTIPLE MYELOMA | USP7, USP1, USP3 | USP7 1/4885USP19 8/4885MEN1 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.